Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
21.12
+0.87 (4.30%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Castle Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 339.92 | 344.23 | 332.07 | 219.79 | 137.04 | 94.09 | |
Revenue Growth (YoY) | -2.06% | 3.66% | 51.09% | 60.38% | 45.65% | 50.18% |
Cost of Revenue | 75.18 | 71.03 | 60.21 | 44.98 | 32.01 | 15.82 |
Gross Profit | 264.74 | 273.2 | 271.86 | 174.81 | 105.03 | 78.26 |
Selling, General & Admin | 235.6 | 229.32 | 200.05 | 180.15 | 143 | 86.74 |
Depreciation & Amortization Expenses | 8.74 | 34.84 | 11.11 | 9.01 | 8.27 | 1.96 |
Research & Development | 53.69 | 51.85 | 52.04 | 53.62 | 44.9 | 29.65 |
Other Operating Expenses | - | - | - | - | -18.29 | - |
Total Operating Expenses | 298.03 | 316.01 | 263.19 | 242.78 | 177.89 | 118.34 |
Operating Income | -33.29 | -42.81 | 8.67 | -67.98 | -72.86 | -40.08 |
Interest Income | 16.13 | 13.24 | 13.47 | 10.62 | 3.97 | 0.07 |
Interest Expense | -0.2 | -0.09 | -0.58 | -0.01 | -0.02 | -0 |
Other Non-Operating Income (Expense) | -0.49 | - | - | - | - | - |
Total Non-Operating Income (Expense) | 15.44 | 13.15 | 12.89 | 10.61 | 3.95 | 0.07 |
Pretax Income | -17.85 | -29.66 | 21.56 | -57.37 | -68.9 | -40.01 |
Provision for Income Taxes | 4.51 | -5.36 | 3.32 | 0.1 | -1.77 | 8.72 |
Net Income | -22.36 | -24.3 | 18.25 | -57.47 | -67.14 | -48.73 |
Net Income to Common | -22.36 | -24.3 | 18.25 | -57.47 | -67.14 | -48.73 |
Shares Outstanding (Basic) | 29 | 29 | 28 | 27 | 26 | 25 |
Shares Outstanding (Diluted) | 29 | 29 | 29 | 27 | 26 | 25 |
Shares Change (YoY) | 0.76% | -0.92% | 9.15% | 2.87% | 3.65% | 32.80% |
EPS (Basic) | -0.43 | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 |
EPS (Diluted) | -0.44 | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 |
Free Cash Flow | 4.52 | 28.33 | 36.54 | -19.25 | -47.29 | -22.47 |
Free Cash Flow Growth | -84.05% | -22.48% | - | - | - | - |
Free Cash Flow Per Share | 0.15 | 0.98 | 1.25 | -0.72 | -1.81 | -0.89 |
Gross Margin | 77.88% | 79.37% | 81.87% | 79.53% | 76.64% | 83.18% |
Operating Margin | -9.79% | -12.44% | 2.61% | -30.93% | -53.16% | -42.60% |
Profit Margin | -6.58% | -7.06% | 5.49% | -26.15% | -48.99% | -51.80% |
FCF Margin | 1.33% | 8.23% | 11.00% | -8.76% | -34.51% | -23.88% |
EBITDA | -18.35 | -2.04 | 24.67 | -55.65 | -62.31 | -36.67 |
EBITDA Margin | -5.40% | -0.59% | 7.43% | -25.32% | -45.47% | -38.98% |
EBIT | -33.29 | -42.81 | 8.67 | -67.98 | -72.86 | -40.08 |
EBIT Margin | -9.79% | -12.44% | 2.61% | -30.93% | -53.16% | -42.60% |
Effective Tax Rate | -25.26% | 18.06% | 15.39% | -0.18% | 2.56% | -21.79% |